Rocket Pharmaceuticals Inc RCKT

US Biotechnology

$2.60 ▼ -3.53% ($-0.10)

📉 Near 52W Low ⬇️ Below Yest. Low

Open $2.80

Prev Close $2.69

Day Range $2.57 – $2.80

52W Range $2.53 – $5.45

Market Cap $284.87M

Beta 0.49

EPS (TTM) $-0.18

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2015-02-18
Shares Out.	109,190,000
Website	rocketpharma.com/ ↗
Phone	13026365400
Employees	202
Revenue	$0
Gross Profit	$0
Net Income	$123.2M
Free Cash Flow	-$170.4M
Total Assets	$423.1M
Total Liabilities	$54.3M
Equity	$368.8M

About Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.

Rocket Pharmaceuticals Inc is a publicly traded company under the ticker symbol RCKT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.